STAAR Surgical - STAA Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STAA shares.
View STAA analyst ratings or view top-rated stocks.

10 equities research analysts have issued 12 month price objectives for STAAR Surgical's stock. Their STAA share price forecasts range from $60.00 to $125.00. On average, they expect the company's share price to reach $82.20 in the next twelve months. This suggests a possible upside of 28.5% from the stock's current price.
View analysts price targets for STAA or view top-rated stocks among Wall Street analysts.

STAAR Surgical's stock was trading at $48.54 on January 1st, 2023. Since then, STAA stock has increased by 31.7% and is now trading at $63.95.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our STAA earnings forecast.

STAAR Surgical (NASDAQ:STAA) announced its earnings results on Wednesday, November, 3rd. The medical instruments supplier reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.01. The medical instruments supplier had revenue of $58.35 million for the quarter, compared to analyst estimates of $57.70 million. STAAR Surgical had a trailing twelve-month return on equity of 12.91% and a net margin of 13.63%. During the same quarter in the prior year, the company posted $0.14 EPS.

ETFs with the largest weight of STAAR Surgical (NASDAQ:STAA) stock in their portfolio include Janus Henderson Small Cap Growth Alpha ETF (JSML), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Pacer US Export Leaders ETF (PEXL), Janus Henderson US Sustainable Equity ETF (SSPX), Pacer Lunt MidCap Multi-Factor Alternator ETF (PAMC) and AI Powered Equity ETF (AIEQ).

STAAR Surgical updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $340.00 million-$340.00 million, compared to the consensus revenue estimate of $343.34 million.

6 employees have rated STAAR Surgical Chief Executive Officer Caren Mason on Glassdoor.com. Caren Mason has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include Tesla (TSLA), NVIDIA (NVDA), PayPal (PYPL), Walt Disney (DIS), CrowdStrike (CRWD), DocuSign (DOCU), Shopify (SHOP), Trade Desk (TTD), Teladoc Health (TDOC) and Roku (ROKU).

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

Shares of STAA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STAA stock can currently be purchased for approximately $63.95.

STAAR Surgical (NASDAQ:STAA) has a market capitalization of $3.08 billion and generates $284.39 million in revenue each year. The medical instruments supplier earns $38.76 million in net income (profit) each year or $0.78 on an earnings per share basis.

The company employs 692 workers across the globe.

STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The official website for the company is www.staar.com. The medical instruments supplier can be reached via phone at (626) 303-7902, via email at bmoore@staar.com, or via fax at 626-303-2962.